In premenopausal breast cancer patients without tamoxifen, goserelin reduced first-event risk by 32% (P = 0.005) at median follow-up of 12.3 years.
In plain wordsIn premenopausal breast cancer patients without tamoxifen, goserelin reduced first-event risk versus no endocrine therapy.
- Peptide
- Goserelin
- Outcome
- DecreaseFirst event risk
- Study
n: not reported in source
- Comparator
- No endocrine therapy, without tamoxifen
- Outcome group
- Tumor growth · Cancer
- Studied dose
- Dose not stated · 2 yearsAs given in this study (human).
Measurements
- Reduction in risk of first event
- 32%
- Goserelin without tamoxifen
Source sentences
In this Stockholm sub-study, at a median follow-up of 12.3 years, goserelin reduced the risk of first event by 32% (P = 0.005) in the absence of tamoxifen, and tamoxifen reduced the risk by 27% (P = 0.018) in the absence of goserelin.
2 context sentences(design, population, supporting numbers)
They were randomly allocated in a 2 × 2 factorial study design to goserelin, tamoxifen, the combination of goserelin and tamoxifen or no endocrine therapy for 2 years, with or without chemotherapy.
This is formally not a preplanned subset analysis presenting the end point first event.